The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer.
Constantin TA, Varela-Carver A, Greenland KK, de Almeida GS, Olden E, Penfold L, Ang S, Ormrod A, Leach DA, Lai CF, Ainscow EK, Bahl AK, Carling D, Fuchter MJ, Ali S, Bevan CL.
Constantin TA, et al. Among authors: de almeida gs.
Br J Cancer. 2023 Jun;128(12):2326-2337. doi: 10.1038/s41416-023-02252-8. Epub 2023 Apr 19.
Br J Cancer. 2023.
PMID: 37076563
Free PMC article.